- Previous Close
42.57 - Open
42.71 - Bid 42.91 x --
- Ask 42.93 x --
- Day's Range
42.52 - 43.07 - 52 Week Range
25.33 - 43.07 - Volume
34,180 - Avg. Volume
180,877 - Market Cap (intraday)
18.834B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.02 - Earnings Date Mar 5, 2025
- Forward Dividend & Yield 0.45 (1.06%)
- Ex-Dividend Date May 3, 2024
- 1y Target Est
--
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.
www.sandoz.com22,633
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: SDZZ.XC
View MorePerformance Overview: SDZZ.XC
Trailing total returns as of 1/24/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SDZZ.XC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SDZZ.XC
View MoreValuation Measures
Market Cap
18.42B
Enterprise Value
18.06B
Trailing P/E
--
Forward P/E
13.79
PEG Ratio (5yr expected)
0.82
Price/Sales (ttm)
2.00
Price/Book (mrq)
2.42
Enterprise Value/Revenue
1.97
Enterprise Value/EBITDA
26.41
Financial Highlights
Profitability and Income Statement
Profit Margin
-0.08%
Return on Assets (ttm)
0.81%
Return on Equity (ttm)
-0.06%
Revenue (ttm)
10.11B
Net Income Avi to Common (ttm)
-8M
Diluted EPS (ttm)
-0.02
Balance Sheet and Cash Flow
Total Cash (mrq)
701M
Total Debt/Equity (mrq)
53.12%
Levered Free Cash Flow (ttm)
1.62B